DEFA14A: Masimo Urges Stockholders to Vote for Company Nominees Amidst Control Battle with Politan

Masimo is urging stockholders to vote for its director nominees, Joe Kiani and Christopher Chavez, citing concerns over Politan's intentions and Quentin Koffey's actions.

Summary

• Masimo is in a proxy battle with Politan Capital Management, with the annual meeting scheduled for September 19, 2024.
• Masimo alleges that Politan's Quentin Koffey has been executing a multi-year plan to take control of Masimo and has acted against the best interests of Masimo's stockholders.
• Masimo claims Politan raised nearly $440 million specifically targeting Masimo stock, without proper disclosure of investors.
• The company accuses Koffey of secretly seeking damaging information about Masimo from former employees and intimidating non-Politan directors.
• Masimo also alleges that Koffey has sabotaged the process of separating the consumer business.
• Masimo urges stockholders to vote for its director nominees, Joe Kiani and Christopher Chavez, to protect the company's future and their investment.
• Masimo reaffirms its commitment to finding the optimal value-maximizing structure to separate its consumer business and improve its governance.
• The company highlights its increased revenue guidance for full-year 2024 and its success in patent infringement cases.
• Masimo emphasizes the potential loss of key personnel, including Joe Kiani, if Politan gains control.

Sentiment

Score: 4

Explanation: The document expresses a negative sentiment due to the ongoing proxy battle and accusations against Politan. While Masimo highlights some positive aspects, the overall tone is defensive and concerned about the future.

Positives

• Masimo has increased revenue guidance for full-year 2024.
• The company has a history of successfully defending its patents, including a recent case against Apple.
• Masimo is committed to separating its consumer business to maximize stockholder value.
• The company is improving its governance by declassifying its Board.
• Masimo has strong momentum due to increased market share gains and returning in-hospital patient census.

Negatives

• Masimo is facing a proxy battle with Politan Capital Management, creating uncertainty and potential disruption.
• Quentin Koffey is accused of acting against the best interests of Masimo's stockholders and violating disclosure obligations.
• The company alleges that Koffey has sabotaged the process of separating the consumer business.
• There is a risk of losing key personnel, including Joe Kiani, if Politan gains control.

Risks

• The ongoing proxy battle with Politan could lead to significant changes in the company's leadership and direction.
• Failure to successfully separate the consumer business could negatively impact stockholder value.
• The loss of key personnel, including Joe Kiani, could harm Masimo's innovation and growth.
• Uncertainties regarding future actions that may be taken by Politan in furtherance of its nomination of director candidates for election at the 2024 Annual Meeting.
• The potential cost and management distraction attendant to Politans nomination of director nominees at the 2024 Annual Meeting or to the Litigation.

Future Outlook

Masimo is committed to finding the optimal value-maximizing structure to separate its consumer business and improve its governance. The company expects to expand its Board to 9 to 11 members with highly-qualified, additive independent directors and will fully declassify the board by the 2026 annual meeting.

Management Comments

• 'We strongly believe that Quentin Koffey, if he were to win two more seats and take control of the Companys Board, will destroy Masimos innovation engine, credibility, growth and stock price.'
• 'Giving Quentin Koffey control of Masimos future puts the value of your investment at real risk, not only because of his track record of misleading statements and hidden intentions, but because with his take over, we will lose Joe Kiani, as well as other top executives and potentially hundreds of key employees.'

Industry Context

The proxy battle highlights the increasing prevalence of activist investors seeking to influence corporate strategy and governance. The focus on separating the consumer business reflects a broader trend of companies streamlining operations to focus on core competencies and unlock value.

Comparison to Industry Standards

• Masimo's success in patent litigation, including the case against Apple, demonstrates its commitment to protecting its intellectual property, similar to how companies like Qualcomm and Ericsson defend their patents in the technology sector.
• The company's efforts to improve patient safety align with industry-wide initiatives to reduce medical errors and improve healthcare outcomes, as seen in the work of organizations like the Institute for Healthcare Improvement (IHI).
• Masimo's focus on noninvasive monitoring technologies positions it as a leader in a growing market, competing with companies like Medtronic and Philips Healthcare.

Corporate Governance

Legal Proceedings

• Masimo has initiated litigation against Politan Capital Management LP and its affiliates.

Stakeholder Impact

• Shareholders face uncertainty due to the proxy battle and potential changes in company direction.
• Employees may experience anxiety and potential job losses if Politan gains control.
• Customers could be affected by changes in product development and service if the company's strategy shifts.
• Suppliers may face changes in procurement practices depending on the outcome of the proxy battle.

Next Steps

• Stockholders need to vote on the updated GOLD proxy card.
• Masimo will continue to evaluate the optimal structure for separating its consumer business.
• The company will continue its litigation against Politan Capital Management.
• Masimo will expand its Board to 9 to 11 members with highly-qualified, additive independent directors.

Key Dates

Keywords

Masimo, Politan, proxy contest, Quentin Koffey, Joe Kiani, stockholders, board of directors, annual meeting, consumer business, governance, patient safety